Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognoses.
Noah S. Kalman, MD, MBA, a radiation oncologist specializing in the treatment of gynecologic, head and neck, thoracic and pediatric cancers, melanoma and non-melanoma skin cancers, and sarcoma at Miami Cancer Institute of Baptist Health Medical Group, discusses the most common types of thyroid cancer and their respective prognoses. He also highlights some of the available treatment options for patients with this disease.
Kalman explains that the most common type of thyroid cancer is papillary thyroid cancer, followed by follicular thyroid cancer. Both of these diseases are classified as differentiated thyroid cancers with treatment primarily involving surgery—either total or partial thyroidectomy.
For patients who undergo total thyroidectomy, radioactive iodine is typically administered as a key treatment option. For those with more advanced disease, they may receive additional therapies, including tyrosine kinase inhibitors and other targeted treatments.
Transcription:
0:09 | The most common kind of thyroid cancer that we see is papillary thyroid cancer, which falls under the category of differentiated thyroid cancers. Papillary is the most common, and then follicular thyroid cancer is sort of second on the list. Then, there are some other different subtypes that we see as well. And then, there are some dedifferentiated thyroid cancers that are much less common.
0:44 | For thyroid cancers, particularly papillary thyroid cancers and follicular thyroid cancers, the mainstay of treatment is surgery, whether total thyroidectomy or partial. And then for those that have disease that there is enough and that requires a total thyroidectomy, I will commonly treat them with radioactive iodine, which is sort of the other mainstay treatment and is the one of the original targeted therapies that has been around for decades and decades. And then for patients with more advanced disease, there are other therapies like tyrosine kinase inhibitors and other targeted therapies that are used.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More